---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-041020"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2026-09-01T20:30:23+00:00"
generated_at: "2026-09-01T20:31:27.994780+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# bioAffinity advances CyPath Lung for surveillance of lung cancer survivors

## Summary
- Announces potential use of CyPath Lung for post-treatment surveillance; >680,000 Americans living with prior lung cancer diagnosis.
- NSCLC recurrence after curative treatment runs 20-55%; ASCO recommends imaging every 6 months for 2 years.
- CyPath Lung detection trial: 92% sensitivity, 87% specificity, 88% accuracy, 99% NPV; not yet validated for surveillance.
- Company cites 3 years of commercial experience and case studies supporting risk stratification of challenging nodules.

## SEC filing metadata
- accession: 0001493152-26-041020
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2026-09-01T20:30:23+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315226041020/0001493152-26-041020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315226041020/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-041020
- JSON: https://secwatch.observer/filing/0001493152-26-041020.json
- Plain text: https://secwatch.observer/filing/0001493152-26-041020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.